STOCK TITAN

Emergent BioSolutions Announces Retirement of Dr. Louis W. Sullivan from Board of Directors

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
management

Emergent BioSolutions (NYSE: EBS) announced that Dr. Louis W. Sullivan will retire from the company’s Board of Directors effective November 14, 2025 after 19 years of service.

Dr. Sullivan joined the board in 2006 and most recently served as chair of the compensation committee and as a member of the nominating and corporate governance committee. The company noted his experience in healthcare, government and biotechnology and cited his role guiding decisions during Emergent’s multi-year transformation. Dr. Sullivan previously served as president of Morehouse School of Medicine and as Secretary of the Department of Health and Human Services.

Loading...
Loading translation...

Positive

  • None.

Negative

  • None.

News Market Reaction

-4.53%
1 alert
-4.53% News Effect

On the day this news was published, EBS declined 4.53%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

GAITHERSBURG, Md., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE: EBS) announced today that Dr. Louis W. Sullivan will retire from the company’s Board of Directors effective November 14 after 19 years of service to the company and its shareholders.

“For nearly two decades, Dr. Sullivan has been a trusted advisor and champion of Emergent’s mission to protect and save lives,” said Joe Papa, president and CEO of Emergent. “On behalf of the Board and the entire Emergent team, I want to thank him for his distinguished leadership and contributions. We wish him all the best.”

Dr. Sullivan served on Emergent’s Board of Directors since 2006, and most recently served as chair of the compensation committee and a member of the nominating and corporate governance committee. His independence and experience in healthcare, government and biotechnology helped guide critical decisions through Emergent’s history, including its current multi-year transformation. He served as president of Morehouse School of Medicine from 1981 to 1989 and from 1993 to 2002 and was Secretary of the Department of Health and Human Services from 1989 to 1993.

AboutEmergent BioSolutions 
At Emergent, our mission is to protect and save lives. For over 25 years, we’ve been at work preparing those entrusted with protecting public health. We deliver protective and life-saving solutions for health threats like smallpox, mpox, botulism, Ebola, anthrax and opioid overdose emergencies. To learn more about how we help prepare communities around the world for today’s health challenges and tomorrow’s threats, visit our website and follow us on LinkedIn, X, Instagram, Apple Podcasts and Spotify.  

Investor Contact: 
Richard S. Lindahl 
Executive Vice President, CFO 
lindahlr@ebsi.com

Media Contact: 
Assal Hellmer 
Vice President, Communications 
mediarelations@ebsi.com 


FAQ

When does Dr. Louis W. Sullivan retire from the Emergent BioSolutions board (EBS)?

Dr. Louis W. Sullivan will retire effective November 14, 2025.

How long did Dr. Louis W. Sullivan serve on Emergent BioSolutions' (EBS) board?

He served on the board since 2006, totaling 19 years of service.

What roles did Dr. Louis W. Sullivan hold on the Emergent BioSolutions (EBS) board?

He most recently served as chair of the compensation committee and as a member of the nominating and corporate governance committee.

Will Emergent BioSolutions (EBS) name a replacement for Dr. Sullivan on the board?

The announcement did not specify a replacement or timing for filling the board seat.

What past public service and academic roles does Dr. Louis W. Sullivan have?

He served as president of Morehouse School of Medicine and as Secretary of the Department of Health and Human Services.

Did Emergent BioSolutions (EBS) cite reasons for Dr. Sullivan’s retirement?

The company announced the retirement as an effective personnel change and thanked him for his service; no additional reasons were provided.
Emergent Biosolutions Inc

NYSE:EBS

EBS Rankings

EBS Latest News

EBS Latest SEC Filings

EBS Stock Data

595.58M
50.96M
2.84%
70.19%
16.33%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States
GAITHERSBURG